Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database
PLOS One · 09.07.2025 · 20 (7) · e0327500
DOI: 10.1371/journal.pone.0327500 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 09.07.2025. Verfasst von Lu Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Chemical and Drug Induced Liver Injury, Pharmacovigilance. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Pharmaceutical Scientific Research Foundation of the Chengdu Pharmaceutical Association.
Abstract (Originalsprache)
Background
Statins are commonly prescribed in clinical practice and are associated with a high risk of drug-induced liver injury (DILI). This study aims to examine the real-world data on statin-induced liver injury to assess medication safety.
Methods
All DILI cases reported with statins as primary suspected drugs were extracted based on the US Food and Drug Administration adverse event reporting system (FAERS) from 2004 to 2023. A disproportional analysis was conducted using reported odds ratios (ROR) and information component (IC) to assess the significant association between statins and DILI.
Results
A total of 7779 statin-associated DILI cases were identified. DILI patients tended to be aged >65 years (45.43%), with more females than males (48.80% vs 43.75%), and 39.95% of DILI patients required hospitalization. Statin-induced DILI cases are most commonly reported with atorvastatin (53.48%), rosuvastatin (20.44%), and simvastatin (19.46%). The DILI signals (ROR; 95% CI) for statins were ranked as follows: fluvastatin (6.90; 5.89–8.10)> atorvastatin (3.09; 2.99–3.19)> simvastatin (2.96; 2.81–3.12)> lovastatin (2.77; 2.17–3.53)> rosuvastatin (2.27; 2.16–2.39)> pravastatin (2.07; 1.81–2.37). Age-stratified analysis showed that a stronger signal was detected in patients (aged ≥65 years) than patients (aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
ORCID-Profile: Bin Wu
Förderung
- the Pharmaceutical Scientific Research Foundation of the Chengdu Pharmaceutical Association
Zitieren
APA
Zhou, L., Wu, B., Bian, Y., Lu, Y., Zou, Y., Lin, S., Li, Q., & Liu, C. (2025). Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database. PLOS One, 20(7), e0327500. https://doi.org/10.1371/journal.pone.0327500
Vancouver
Zhou L, Wu B, Bian Y, Lu Y, Zou Y, Lin S, et al. Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database. PLOS One. 2025;20(7):e0327500. doi:10.1371/journal.pone.0327500
BibTeX
@article{Zhou2025,
author = {Zhou, Lu and Wu, Bin and Bian, Yuan and Lu, Yun and Zou, Ya and Lin, Shanshan and Li, Qinchuan and Liu, Chun},
title = {Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0327500},
doi = {10.1371/journal.pone.0327500}
}
EUVIMED